Last reviewed · How we verify
NCT05233293
Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma
NA trial testing Spyglass + RFA in Extrahepatic Cholangiocarcinoma in 200 participants. Status unknown.
1 October 2023
Quick facts
| Lead sponsor | First People's Hospital of Hangzhou |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 January 2021 |
| Primary completion | 1 October 2023 |
| Estimated completion | 31 October 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Spyglass + RFA
- Cytobrush + RFA
Conditions studied
- Extrahepatic Cholangiocarcinoma — all drugs for Extrahepatic Cholangiocarcinoma →
- Malignant Biliary Obstruction — all drugs for Malignant Biliary Obstruction →
Sponsor
First People's Hospital of Hangzhou
Who can join
18 and older, any sex, with Extrahepatic Cholangiocarcinoma or Malignant Biliary Obstruction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the development of endoscopic technology, endoscopic retrograde cholangiopancreatography (ERCP) has been widely used in the diagnosis and treatment of extrahepatic cholangiocarcinoma.In patients with extrahepatic cholangiocarcinoma, cytological brushing performed concurrently with ERCP had a lower pathologically positive rate and increased the times of ERCPs, increased the risk of postoperative complications at the same time.The present study aims to compare the efficacy and safety outcomes of Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05233293
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Extrahepatic Cholangiocarcinoma
Currently open trials in the same condition.
- NCT07235007 — Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic C · NA · recruiting
- NCT06101277 — Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) · NA · recruiting
- NCT05519319 — Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma · NA · recruiting
- NCT07176962 — A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening · recruiting
Other First People's Hospital of Hangzhou trials
Trials by the same sponsor.
- NCT07507825 — Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) · Phase 2 · not yet recruiting
- NCT07390981 — Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder · NA · not yet recruiting
- NCT07242443 — Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Py · Phase 4 · not yet recruiting
- NCT07207278 — Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma · recruiting
- NCT06933992 — Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05233293 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First People's Hospital of Hangzhou
- Last refreshed: 15 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05233293.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing